InvestorsHub Logo
Followers 3344
Posts 84621
Boards Moderated 6
Alias Born 10/05/2005

Re: None

Tuesday, 05/14/2019 4:13:13 AM

Tuesday, May 14, 2019 4:13:13 AM

Post# of 14944
Scilex Pharmaceuticals Inc. (“Scilex”), a subsidiary of Sorrento Therapeutics, Inc. (the “Company”), announced that net sales of ZTlido® (lidocaine topical system 1.8%) for the quarter ended March 31, 2019 were approximately $2.8 million and net sales of ZTlido® for the month of April 2019 were approximately $1.8 million. The Company also announced that according to latest market share data from iQivia, ZTlido® now has approximately a 4% share of the total lidocaine new prescription market in the U.S., having already surpassed Lidoderm’s market share. The preliminary information presented in this Current Report on Form 8-K is based on the Company’s current expectations and may be adjusted as a result of, among other things, completion of customary quarterly review procedures.

https://ih.advfn.com/stock-market/NASDAQ/sorrento-therapeutics-inc-SRNE/stock-news/79901878/current-report-filing-8-k

Lets exchange member marks and exchange market moving information today!

All my posts are strictly my opinion only! Please do your own DD.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SRNE News